FR06C0021I1 - - Google Patents

Info

Publication number
FR06C0021I1
FR06C0021I1 FR06C0021C FR06C0021I1 FR 06C0021 I1 FR06C0021 I1 FR 06C0021I1 FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 I1 FR06C0021 I1 FR 06C0021I1
Authority
FR
France
Prior art keywords
nucleic acid
vegf nucleic
acid ligand
immunogenic
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/739,109 external-priority patent/US5859228A/en
Priority claimed from US08/870,930 external-priority patent/US6168778B1/en
Priority claimed from US08/897,351 external-priority patent/US6051698A/en
Application filed filed Critical
Publication of FR06C0021I1 publication Critical patent/FR06C0021I1/fr
Application granted granted Critical
Publication of FR06C0021I2 publication Critical patent/FR06C0021I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
FR06C0021C 1996-10-25 2006-07-03 Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire Active FR06C0021I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/739,109 US5859228A (en) 1995-05-04 1996-10-25 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US08/870,930 US6168778B1 (en) 1990-06-11 1997-06-06 Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US08/897,351 US6051698A (en) 1997-06-06 1997-07-21 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
PCT/US1997/018944 WO1998018480A1 (fr) 1996-10-25 1997-10-17 Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire

Publications (2)

Publication Number Publication Date
FR06C0021I1 true FR06C0021I1 (fr) 2006-10-13
FR06C0021I2 FR06C0021I2 (fr) 2007-08-03

Family

ID=27419245

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0021C Active FR06C0021I2 (fr) 1996-10-25 2006-07-03 Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire

Country Status (18)

Country Link
EP (2) EP1685842A3 (fr)
JP (2) JP3626503B2 (fr)
KR (1) KR100514929B1 (fr)
AT (1) ATE318143T1 (fr)
AU (1) AU733674B2 (fr)
CA (1) CA2269072C (fr)
DE (3) DE69735292T2 (fr)
DK (1) DK0957929T3 (fr)
ES (1) ES2259188T3 (fr)
FR (1) FR06C0021I2 (fr)
GE (1) GEP20094799B (fr)
IL (2) IL129497A0 (fr)
LU (1) LU91252I2 (fr)
NL (1) NL300234I2 (fr)
NZ (1) NZ334859A (fr)
PT (1) PT957929E (fr)
RU (1) RU2177950C2 (fr)
WO (1) WO1998018480A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
AU782620B2 (en) * 1991-06-10 2005-08-11 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
WO2001005873A1 (fr) 1999-07-14 2001-01-25 Alza Corporation Lipopolymere neutre et compositions liposomales le contenant
AU2001296305B2 (en) * 2000-09-26 2007-12-06 Duke University RNA aptamers and methods for identifying the same
DK2431377T3 (en) * 2001-10-26 2017-08-14 Noxxon Pharma Ag Modified L-nucleic acids
PL371929A1 (en) * 2001-11-09 2005-07-11 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
EP1543158B1 (fr) 2002-07-25 2011-07-13 Archemix Corp. Compositions therapeutiques aptameriques regulees
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20040197804A1 (en) * 2002-12-03 2004-10-07 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
WO2004094614A2 (fr) 2003-04-21 2004-11-04 Archemix Corp. Aptameres stabilises lies a un facteur de croissance derive de plaquette et leur utilisation en tant qu'agents therapeutiques d'oncologie
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP3736335A1 (fr) 2004-02-12 2020-11-11 Archemix LLC Agents thérapeutiques aptamères utiles dans le traitement de troubles liés à un complément
US20050260153A1 (en) * 2004-04-13 2005-11-24 Pericles Calias Facilitation of iontophoresis using charged moieties
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP3034089A1 (fr) 2004-11-02 2016-06-22 Archemix LLC Aptameres stabilises pour plaquettes derives du facteur de croissance et leur utilisation en tant que produits therapeutiques oncologiques
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
CA2613442C (fr) 2005-06-30 2016-08-23 Archemix Corp. Materiaux et procedes pour la generation de transcriptions d'acide nucleiques modifiee en 2'
WO2007016380A2 (fr) * 2005-07-28 2007-02-08 (Osi) Eyetech, Inc. Dispositifs et methodes d'execution de procedures sur un sein
EP1931352B1 (fr) 2005-08-22 2016-04-13 The Regents of The University of California Agonistes tlr
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
EP1966242A1 (fr) * 2005-12-06 2008-09-10 Domantis Limited Ligands presentant une specificite de liaison avec l'egfr et/ou le vegf et leurs procedes d'utilisation
CA2633063A1 (fr) * 2005-12-16 2007-06-21 Diatos Conjugues peptidiques de penetration cellulaire pour la delivrance d'acides nucleiques dans une cellule
JPWO2007080902A1 (ja) * 2006-01-11 2009-06-11 協和発酵キリン株式会社 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
PL2596807T3 (pl) 2006-03-08 2016-06-30 Archemix Llc Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych
PL2125007T3 (pl) 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
WO2010065671A2 (fr) * 2008-12-04 2010-06-10 Curna, Inc. Traitement de maladies apparentées au facteur de croissance de l'endothélium vasculaire (vegf) par inhibition de la transcription antisens naturelle en vegf
CN104922676B (zh) * 2009-03-20 2019-03-12 Clsn实验室股份有限公司 聚胺衍生物
WO2011061351A1 (fr) 2009-11-23 2011-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Aptamères dirigés contre la protéine de matrice 1 de virus de la grippe de type a et leurs utilisations
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
KR20130136983A (ko) * 2010-09-24 2013-12-13 말린크로트 엘엘씨 치료 및/또는 진단용 나노담체의 목표화를 위한 압타머 접합체
US20150337308A1 (en) 2012-04-11 2015-11-26 Chu De Bordeaux Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
ES2912033T3 (es) 2012-10-23 2022-05-24 Caris Science Inc Aptámeros y usos de los mismos
EP2935628B1 (fr) 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Compositions et procédés pour le criblage d'aptamères
US9850492B2 (en) 2013-03-22 2017-12-26 The University Of Tokyo Aptamer to IL-17 and use thereof
CN105431204A (zh) 2013-07-12 2016-03-23 奥普索特克公司 用于治疗或预防眼科病的方法
KR20160080815A (ko) 2013-08-28 2016-07-08 카리스 라이프 사이언스 스위스 홀딩스 게엠베하 올리고뉴클레오티드 프로브 및 이의 용도
CN112826934A (zh) 2014-12-11 2021-05-25 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
EP3241903A4 (fr) 2014-12-29 2018-07-04 Bonac Corporation Composition contenant de façon stable une molécule d'acide nucléique
CA2979361A1 (fr) 2015-03-09 2016-09-15 Caris Science, Inc. Methode de preparation de bibliotheques d'oligonucleotides
WO2017004243A1 (fr) 2015-06-29 2017-01-05 Caris Science, Inc. Oligonucléotides thérapeutiques
WO2017019918A1 (fr) 2015-07-28 2017-02-02 Caris Science, Inc. Oligonucléotides ciblés
WO2017046140A1 (fr) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne
EP4339288A2 (fr) 2016-03-18 2024-03-20 Caris Science, Inc. Sondes oligonucleotidiques et leurs utilisations
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
AU2017271579B2 (en) 2016-05-25 2023-10-19 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3332812A1 (fr) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Ensemble à base d'acide nucléique et utilisation de l'ensemble dans la thérapie du cancer
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
US11931327B2 (en) 2017-07-04 2024-03-19 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
WO2019210097A1 (fr) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamères ayant une stabilité, une puissance ou une demi-vie pour une sécurité et une efficacité améliorées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503957A (ja) * 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
US5849479A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)

Also Published As

Publication number Publication date
AU4990497A (en) 1998-05-22
DK0957929T3 (da) 2006-07-03
DE69735292D1 (de) 2006-04-27
EP0957929A1 (fr) 1999-11-24
LU91252I2 (fr) 2006-08-14
DE69735292T2 (de) 2006-10-19
AU733674B2 (en) 2001-05-24
EP0957929B1 (fr) 2006-02-22
NZ334859A (en) 2001-02-23
ATE318143T1 (de) 2006-03-15
EP1685842A2 (fr) 2006-08-02
IL129497A0 (en) 2000-02-29
CA2269072C (fr) 2006-02-14
CA2269072A1 (fr) 1998-05-07
GEP20094799B (en) 2009-10-26
WO1998018480A1 (fr) 1998-05-07
EP0957929A4 (fr) 2003-06-25
JP2001505191A (ja) 2001-04-17
FR06C0021I2 (fr) 2007-08-03
RU2177950C2 (ru) 2002-01-10
JP4160038B2 (ja) 2008-10-01
KR100514929B1 (ko) 2005-09-15
NL300234I2 (nl) 2006-10-02
JP2005046160A (ja) 2005-02-24
EP1685842A3 (fr) 2006-11-29
NL300234I1 (nl) 2006-09-01
IL129497A (en) 2009-06-15
DE122006000029I2 (de) 2007-11-08
PT957929E (pt) 2006-06-30
KR20000052697A (ko) 2000-08-25
DE122006000029I1 (de) 2006-10-19
JP3626503B2 (ja) 2005-03-09
ES2259188T3 (es) 2006-09-16

Similar Documents

Publication Publication Date Title
FR06C0021I1 (fr)
EP0824541A4 (fr) Complexes de ligands d'acide nucleique
IL134648A0 (en) Tie ligand homologues
DE69730820D1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
WO1989003041A3 (fr) Conjugue de tridentate et son procede d'utilisation
WO1991001621A3 (fr) Composites et procedes de fabrication
DE69109131D1 (de) Verfahren zur herstellung von molekularsieben, einschliesslich zeolithen, mit metallchelat-komplexen.
IT9048014A0 (it) Trasmissione a pulegge, in particolare per autoveicoli.
ZA967618B (en) Peroxo-containing metal complexes having amine oxide, phosphine oxide, arsine oxide, pyridine N-oxide or pyridine ligants as epoxidation catalysts.
ZA976421B (en) New bis-platinum complexes with polyamine ligands as antitumor agents.
DE69716443T2 (de) Antitumor-wirksame bis-platin komplexe mit polymethylen-derivaten als liganden
IT8919717A0 (it) Equipaggiamento elettrico di trazione, in particolare per veicoli da trasporto pubblico.
DE3880991T2 (de) Aminoanthracendion-bis-platinkomplexe, nützlich als Antitumor-Agenzien.
FI890857A0 (fi) Skaopenhet att placeras under arbetsbord, i synnerhet diskbord, i ett koek.
EP0648217A4 (fr) Ligands nouveaux a base de saccharose, procedes de preparation, complexes de platine en derivant, et procedes concernant leur utilisation.
DE68918620D1 (de) Magnetfluss-Betriebsverfahren für einen Induktionsmotor.
NL189664C (nl) Vorkhefwagen voorzien van een weeginrichting, alsmede vork voor een dergelijke vorkhefwagen.
DE69003107D1 (de) Mit bor komplexierte organische phosphor-verbindungen.
DE58904373D1 (de) Wasserloesliche 2-naphthol-azoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe.
IT8821824A0 (it) Posteggio di presentazione per autoveicoli, in particolare per automobili o autoveicoli per servizio promiscuo.
EP0283754A3 (en) Tungsten oxo-porphyrin complexes
ES2018944A6 (es) Metodos de preparacion de tetraclorometalatos (ii) de 3-dialquil (aril) amino-5-fenil 1,2,4-ditiazolio.
IT1246331B (it) Cuscinetto di spinta di innesto, in particolare per autoveicolo.
ATE89284T1 (de) Aminoanthracendion-bis-platinkomplexe, nuetzlich als antitumor-agenzien.
SI0957929T1 (sl) Kompleksi liganda nukleinske kisline vaskularnegaendotelijskega rastnega faktorja (VEGF)